RxDoctor Payments Data

Jan Sonander, MD

Family Medicine · Santa Rosa, CANPI 1982763959

Payments from drug & device makers

$1,144in general payments, 2019–2025

Across 57 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$484
  • GSK$190
  • Novo Nordisk$159
  • Amgen$113
  • Pfizer$57
  • Lilly USA, LLC$48
  • plus $92 from 4 others

What the payments were for

  • Food & beverage$1,144100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,144 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$285,765
Medicare patients
464
Services billed
2,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$111,370
EliquisApixaban99$98,290
JardianceEmpagliflozin59$63,427
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$52,437
XareltoRivaroxaban39$42,973
JanuviaSitagliptin Phosphate38$37,177
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$18,427
MyrbetriqMirabegron24$14,720
Breo ElliptaFluticasone/Vilanterol32$14,215
Atorvastatin Calcium587$7,638
Levothyroxine Sodium435$5,792
Lactulose97$4,866
Divalproex Sodium61$4,523
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen161$4,472
Tamsulosin Hcl179$4,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$159$111,37093 claims
PfizerEliquis$57$98,29099 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$190$85,07999 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →